Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.52 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471435 | 0.86 | MAPT (0.51) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL15896224 | 0.81 | CA12 (0.56) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL11747282 | 0.78 | GRIN2D (0.73) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL18719807 | 0.76 | HPGD (0.58) | CYP1A2CYP1A1CYP1B1ALDH1A1GRIN2D | |
| SCHEMBL145083 | 0.75 | CYP1A2 (0.76) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL2316541 | 0.75 | GRIN2D (0.64) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL2009040 | 0.75 | GRIN2D (0.64) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL2314671 | 0.75 | GRIN2D (0.64) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL8237102 | 0.75 | GRIN2D (0.64) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 | |
| SCHEMBL13128166 | 0.75 | CYP1A2 (0.63) | MAPTCYP1A2CYP1A1CYP1B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970248-B1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | DISCOVERYBIOMED, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-9815825-B2 | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders | DISCOVERYBIOMED, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014152278-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152213-A2 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | DISCOVERYBIOMED, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024065-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING CYSTIC FIBROSIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND MISFOLDED PROTEIN DISORDERS | CFTR, SLC47A1, ABCB11 | MAPT 3746/4885CYP1A2 1524/4885CYP1A1 1247/4885 |
| US-10369145-B2 | Coumarin derivatives and methods of use in treating hyperproliferative diseases | HSP90B1, HSPD1, HSPE1 | MAPT 3834/4885CYP1A2 3271/4885CYP1A1 3285/4885 |
| US-20160038475-A1 | COUMARIN DERIVATIVES AND METHODS OF USE IN TREATING HYPERPROLIFERATIVE DISEASES | HSP90B1, HSPD1, HSPE1 | MAPT 3834/4885CYP1A2 3271/4885CYP1A1 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.